Literature DB >> 2760101

Cellular and molecular pharmacology of 4'-epidoxorubicin in HeLa cells. Comparison with its parent drug, doxorubicin.

O Cantoni1, P Sestili, F Cattabeni, C Geroni, M Grandi, F C Giuliani.   

Abstract

The effects on cellular DNA and cytotoxicity produced by doxorubicin (Dx) and its epimer 4'-epidoxorubicin (4'E-Dx) were investigated in cultured HeLa cells. 4'E-Dx was 2.3 times more cytotoxic than Dx after 1 h of treatment, but the two anthracyclines were equally cytotoxic on longer-term (24 h) drug exposure. The different kinetics of cell lethality were related to pharmacodynamic differences between the two drugs. In fact, cellular uptake and efflux rates of 4'E-Dx were faster than those of Dx on 1 h of drug exposure but similar after 24 h of treatment. 4'E-Dx caused more protein-concealed strand breaks in DNA (single and double) than did Dx, despite a lower potency for free-radical formation. The degree of strand breakage by 4'E-Dx was not a linear function of exposure time and, in fact, the rate of strand-break induction declined continuously with time. In contrast, Dx caused an almost linear increase in DNA single-strand breaks with time during 1 h of drug exposure; this was apparently due to its slower uptake. There was little repair of the DNA single-strand breaks produced by Dx upon postincubation for 5 h in a drug-free medium, whereas DNA lesions caused by 4'E-Dx were removed with a t1/2 of about 1.7 h. These findings underline the importance of the cellular pharmacokinetics of anthracyclines in relation to their cytotoxic and DNA-damaging effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2760101     DOI: 10.1007/BF00400965

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  16 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

2.  Diminished superoxide anion generation by reduced 5-iminodaunorubicin relative to daunorubicin and the relationship to cardiotoxicity of the anthracycline antitumor agents.

Authors:  J W Lown; H H Chen; J A Plambeck; E M Acton
Journal:  Biochem Pharmacol       Date:  1979-09-01       Impact factor: 5.858

3.  Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.

Authors:  F Arcamone; S Penco; A Vigevani; S Redaelli; G Franchi; A DiMarco; A M Casazza; T Dasdia; F Formelli; A Necco; C Soranzo
Journal:  J Med Chem       Date:  1975-07       Impact factor: 7.446

4.  Biologic characterization and chemotherapeutic response of MS-2 tumor: a non-regressing mouse sarcoma derived from MSV-M-induced sarcoma.

Authors:  F Giuliani; O Bellini; A M Casazza; F Formelli; G Savi; A Di Marco
Journal:  Eur J Cancer       Date:  1978-05       Impact factor: 9.162

5.  X-ray induced DNA double strand break production and repair in mammalian cells as measured by neutral filter elution.

Authors:  M O Bradley; K W Kohn
Journal:  Nucleic Acids Res       Date:  1979-10-10       Impact factor: 16.971

6.  DNA topoisomerases.

Authors:  N R Cozzarelli
Journal:  Cell       Date:  1980-11       Impact factor: 41.582

7.  NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals.

Authors:  N R Bachur; S L Gordon; M V Gee; H Kon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

8.  Comparison of DNA scission and cytotoxicity produced by Adriamycin and 5-iminodaunorubicin in human colon carcinoma cells.

Authors:  J B Johnston; L A Zwelling; D Kerrigan; L S Lloyd; R I Glazer
Journal:  Biochem Pharmacol       Date:  1983-07-15       Impact factor: 5.858

9.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.

Authors:  K M Tewey; T C Rowe; L Yang; B D Halligan; L F Liu
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

10.  Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin.

Authors:  L A Zwelling; S Michaels; L C Erickson; R S Ungerleider; M Nichols; K W Kohn
Journal:  Biochemistry       Date:  1981-11-10       Impact factor: 3.162

View more
  6 in total

1.  Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitro.

Authors:  D Bartkowiak; J Hemmer; E Röttinger
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Comparative effects of doxorubicin and 4'-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell line.

Authors:  O Cantoni; P Sestili; F Cattabeni; C Geroni; F Giuliani
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of epirubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 5.  Epirubicin: a review of its intravesical use in superficial bladder cancer.

Authors:  S V Onrust; L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 4.271

6.  Aneugenic effects of epirubicin in somatic and germinal cells of male mice.

Authors:  Sabry Mohamed Attia; Sheikh Fayaz Ahmad; Radwa Mohamed Okash; Saleh Abdulrahman Bakheet
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.